Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

The Present and Future of Clinical Management in Metastatic Breast Cancer

Version 1 : Received: 15 August 2022 / Approved: 16 August 2022 / Online: 16 August 2022 (09:52:17 CEST)

How to cite: Lin, P.; Laliotis, G. The Present and Future of Clinical Management in Metastatic Breast Cancer. Preprints 2022, 2022080285 (doi: 10.20944/preprints202208.0285.v1). Lin, P.; Laliotis, G. The Present and Future of Clinical Management in Metastatic Breast Cancer. Preprints 2022, 2022080285 (doi: 10.20944/preprints202208.0285.v1).

Abstract

Regardless of the advances in our ability to detect early and treat breast cancer, it is still one of the common types of malignancy worldwide, with the majority of patients decease upon metastatic disease. Nevertheless, due to these advances, we have extensively characterized the drivers and molecular profiling of breast cancer and further dividing it into subtypes. These subgroups are based on immunohistological markers (Estrogen Receptor-ER, Progesterone Receptor-PR and Human Epidermal Growth Factor Receptor 2-HER-2) and transcriptomic signatures, with distinct therapeutic approaches and regiments. These therapeutic approaches include targeted therapy (HER-2+), endocrine therapy (HR+) or chemotherapy (TNBC) with optional combination radiotherapy, depending on clinical stage. Technological and scientific advances in the identification of molecular pathways that contribute to therapy-resistance and establishment of metastatic disease, have provided the rationale for revolutionary targeted approaches against Cyclin-Dependent Kinases 4/6 (CDK4/6), PI3 Kinase (PI3K), Poly ADP Ribose Polymerase (PARP) and Programmed Death-Ligand 1 (PD-L1), among others. In this review, we focus on the comprehensive overview of epidemiology and current standard of care treatment of metastatic breast cancer, along with ongoing clinical trials. Towards this goal, we utilized available literature from PubMed and ongoing clinical trial information from clinicaltrials.gov to reflect the up to date and future treatment options for metastatic breast cancer.

Keywords

Breast; cancer; metastasis; oncology

Subject

LIFE SCIENCES, Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.